Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : MEDICINUS

Analisis In Silico pada VCO untuk Terapi Dermatitis Atopik Mardiana; Primadhanty B; Adniana N; Halim PK; Didik H. Utomo; Endra Yustin Ellistasari; Suci Widhiati
MEDICINUS Vol. 33 No. 3 (2020): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (336.324 KB) | DOI: 10.56951/medicinus.v33i3.74

Abstract

Introduction: In silico analysis is used in the early stages of drug discovery to speed the rate of discovery that is considered cost and time-efficient. Virgin Coconut Oil (VCO) is a treatment option for atopic dermatitis because it has function to repair skin barrier and as anti-inflammation. Objective: To evaluate the VCO content using computational in silico analysis for the treatment of atopic dermatitis. Methods: The active compounds of Cocos nucifera extracted from KNApSAcK database were predicted experimentally and analyzed computationally using Simple Molecular-Input Line-Entry System (SMILES), Prediction of Activity Spectra for biologically active Substances (PASS) server, and Search Tool for Interactions of Chemicals (STITCH). Results: There are 19 active compounds found in VCO. The analysis shows that VCO has free fatty acid (FFA) protein which acts as a receptor for long and medium chain saturated and unsaturated fatty acids. The highest potential bioactivity of active VCO compounds was as antieczema, with the most important component was linoleic acid, with an average value of probable to be active (Pa) = 0.872, predicted to be highly potential in computational and laboratory tests. Conclusion: Based on this study, we recommend the use of VCO as treatment for atopic dermatitis because VCO has anti-inflammatory potential bioactivity, histamine inhibitor, improves skin barrier function and antieczema which could improve the outcome of atopic dermatitis.
Sindrom Kindler Budi Eko Prasetyorini; Suci Widhiati
MEDICINUS Vol. 36 No. 1 (2023): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/medicinus.v36i1.117

Abstract

Kindler syndrome (KS) is a very rare form of epidermolysis bullosa (EB) and is a disease with defective FERMT1 gene. The FERMT1 gene provides the information needed to produce a protein called kindlin-1 where this protein plays an important role in attaching cells to the extracellular matrix which functions to hold, organize and connect cells in the body. Abnormalities in KS cause cells in the extracellular matrix to weaken so that the skin becomes brittle, prone to blisters and sores. Symptoms of SK are characterized by blisters that most often form on the backs of the hands and the tops of the feet, and thin, fragile skin. Mucosa of the eyes, intestines, esophagus, mouth, urinary tract and genitals may be affected. SK sufferers have a high sensitivity to light. Other symptoms can include discolored skin, thickened skin on the palms and soles and skin thatis atrophied or thin, dry and wrinkled. These symptoms appear in infancy and continue into adulthood, the risk of gingivitis (inflammation of the gums) which can lead to periodontitis or gum disease, throat, eye problems, higher risk of developing skin cancer and intestinal bleeding. Kindler syndrome management is basically preventive and symptomatic. Good wound care including the use of topical and systemic antibiotics for infected and ulcerated bullous lesions can reduce morbidity. Educating the patient to avoid trauma can help prevent blister formation.